Gossamer Bio Inc. (NASDAQ: GOSS) reported Q2 EPS of $0.22, $0.29 worse than the analyst estimate of $0.51. Revenue for the quarter came in at $95.84 million versus the consensus estimate of $114.29 million.

For earnings history and earnings-related data on Gossamer Bio Inc. (GOSS) click here.